Demethylasterriquinone B1  (Synonyms: DAQ B1; L-783281; Dimethylasterriquinone)

Demethylasterriquinone B1 (DAQ B1; L-783281) is an orally active insulin receptor (insulin receptor) agonist and AKT activator. By activating AKT, Demethylasterriquinone B1 upregulates the expression and activity of eNOS to increase NO production, while downregulating the expression of the NADPH oxidase subunit p22phox to reduce oxidative stress and improve vascular endothelial dysfunction in hypertensive rats. Demethylasterriquinone B1 combind with an AKT inhibitor targets the insulin signaling pathway to activate two antiviral pathways, RNA interference and JAK/STAT, in mosquitoes, thereby reducing Zika virus infection^[1][2][3].

Demethylasterriquinone B1 (1 μM; 24 h) activates the AKT/FOXO insulin signaling pathway, increases the phosphorylation level of ERK, and upregulates the RNAi marker AGO2 in Aedes aegypti Aag2 cells^[2].
Demethylasterriquinone B1 (1 μM; 24 h) significantly reduces Zika virus replication levels in Aedes aegypti Aag2 cells on day 1 and day 3 post-infection^[2].
Demethylasterriquinone B1 (1 μM; 24 h) exerts antiviral activity against Zika virus in Aedes aegypti Aag2 cells, and this activity depends on functional RNAi and JAK/STAT signaling pathways^[2].
Demethylasterriquinone B1 (10-50 µM) effectively reverses insulin resistance induced by PC-1 overexpression and TNF-α inflammation in HTC-IR cells, but has no effect on resistance induced by PKC activation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Demethylasterriquinone B1 (5 mg/kg; p.o.; once daily; 1 week) ameliorates hypertension-related vascular endothelial dysfunction in male Sprague Dawley rats by restoring eNOS activity, alleviating oxidative stress, and reducing mean arterial pressure, and its effects are dependent on eNOS activity^[1].
Combination treatment with demethylasterriquinone B1 (10 μM; p.o.; single administration) and an AKT inhibitor reduces ZIKV infection rate and viral titer in Aedes aegypti, and induces activation of the RNAi and JAK/STAT antiviral pathways, with the induction level of immune genes peaking at 7 days post-infection^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

506.59

C₃₂H₃₀N₂O₄

78860-34-1

Solid

Brown to reddish brown

C=CC(C)(C1=C(C(C(C(O)=C2C3=CNC4=C3C=CC=C4C/C=C(C)/C)=O)=C(O)C2=O)C5=C(C=CC=C5)N1)C

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Li M, et al. Small molecule insulin receptor activators potentiate insulin action in insulin-resistant cells. Diabetes. 2001 Oct;50(10):2323-8.
   [Content Brief]

  [2]. Shah DI, et al. Effect of demethylasterriquinone b1 in hypertension associated vascular endothelial dysfunction. Int J Cardiol. 2007;120(3):317-324.  [Content Brief]

  [3]. Trammell CE, et al. Coupled small molecules target RNA interference and JAK/STAT signaling to reduce Zika virus infection in Aedes aegypti. PLoS Pathog. 2022;18(4):e1010411. Published 2022 Apr 4.  [Content Brief]